Li Weng is a seasoned R&D leader with 20 years of research experience in genomic science. Over the years, Dr. Weng has built up broad and in-depth knowledge of different technology platforms, including sequencing and microarray. She currently serves as SVP, Head of R&D at AccuraGen, leading the innovation of next generation sequencing (NGS) based liquid biopsy tests for personalized medicine. Before AccuraGen, Dr. Weng was the Associate Director of R&D at Adaptive Biotechnologies/Sequenta where she spearheaded the development of clonoSEQ, the first NGS based Minimal Residual Disease (MRD) test that received FDA clearance for hematological malignancies. Prior to Adaptive Biotechnologies/Sequenta, Dr. Weng served as an R&D scientist at Affymetrix where she played a major role in the development of multiple high throughput whole genome genotyping and copy number variant (CNV) detection products.
Dr. Weng earned her Ph.D degree in Cancer Biology from University of Chicago and received post-doc training at Lawrence Berkeley National Laboratory/Joint Genome Institute. She is passionate about applying genomic technologies to advance modern medicine and improve human health.
Li Weng is a seasoned R&D leader with 20 years of research experience in genomic science. Over the years, Dr. Weng has built up broad and in-depth knowledge of different technology platforms, including sequencing and microarray. She currently serves as SVP, Head of R&D at AccuraGen, leading the innovation of next generation sequencing (NGS) based liquid biopsy tests for personalized medicine. Before AccuraGen, Dr. Weng was the Associate Director of R&D at Adaptive Biotechnologies/Sequenta where she spearheaded the development of clonoSEQ, the first NGS based Minimal Residual Disease (MRD) test that received FDA clearance for hematological malignancies. Prior to Adaptive Biotechnologies/Sequenta, Dr. Weng served as an R&D scientist at Affymetrix where she played a major role in the development of multiple high throughput whole genome genotyping and copy number variant (CNV) detection products.
Dr. Weng earned her Ph.D degree in Cancer Biology from University of Chicago and received post-doc training at Lawrence Berkeley National Laboratory/Joint Genome Institute. She is passionate about applying genomic technologies to advance modern medicine and improve human health.